HCPLive Network

Aspirin Benefit in Colon Cancer Varies With HLA I Antigen

TUESDAY, April 1, 2014 (HealthDay News) -- Aspirin use after colon cancer diagnosis improves survival if tumors express human leukocyte antigen (HLA) class I antigen, according to a study published online March 31 in JAMA Internal Medicine.

Marlies S. Reimers, MD, from Leiden University Medical Center in the Netherlands, and colleagues modeled survival in a cohort study with tumor blocks from 999 patients with colon cancer, surgically resected between 2002 and 2008. HLA class I antigen and prostaglandin endoperoxide synthase 2 (PTGS2) expression were analyzed, and mutation analysis of PIK3CA was conducted. A prescription database was used to obtain data on aspirin use after diagnosis.

The researchers found that the adjusted rate ratio for the overall survival benefit associated with aspirin use after colon cancer diagnosis was 0.53 (P < 0.001) when tumors expressed HLA class I antigen and 1.03 (P = 0.91) when HLA antigen was lost. A similar benefit of aspirin was seen for tumors with strong and weak PTGS2 expression (rate ratios, 0.68 and 0.59, respectively) and for wild-type PIK3CA tumors (rate ratio, 0.55). There was no correlation noted for mutated PIK3CAtumors (rate ratio, 0.73; P = 0.44).

"Aspirin use after colon cancer diagnosis was associated with improved survival if tumors expressed HLA class I antigen," the authors write. "HLA class I antigen might serve as a predictive biomarker for adjuvant aspirin therapy in colon cancer."

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2014 HealthDay. All rights reserved.

Further Reading
New research shows that a lower dose of aspirin can provide the benefits of preventing certain cancers, without the adverse effects.
Factors such as the aging and growth of the population accompanied by improvements in early detection and treatment are expected to contribute to the growth of the number of cancer survivors in the United States, according to research published online June 1 in CA: A Cancer Journal for Clinicians.
According to a report issued yesterday by the CDC, deaths from colon cancer are declining all over the nation, except in one state.
The oncogenic microRNA (miRNA) miR-21 is a potential biomarker for detection and prognosis of colorectal cancer (CRC).
The likelihood that patients will suffer a return of colon cancer more than doubles if they eat fish less than twice a week, or if they get less than 60 minutes of moderate exercise a week, researchers reported at the annual meeting of the American Society of Clinical Oncology, held from May 30 to June 3 in Chicago.
Under current quality measures, colorectal screenings are being overused in sick elderly patients and underused in healthy ones.
Despite many technological advances, better training and education are the most important factors to boost the detection of adenomas in the colon and reduce interval colorectal cancer.
More Reading